Education
About Us
Working with TipRanks
Follow Us
Alterity Therapeutics Ltd. (AU:ATH)
ASX:ATH
Total Valuation
Alterity Therapeutics has a market cap or net worth of $119.63M. The enterprise value is AU$38.08M.
Market Cap$119.63M
Enterprise ValueAU$38.08M
Share Statistics
Alterity Therapeutics has 10,875,416,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding10,875,416,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Alterity Therapeutics’s return on equity (ROE) is -0.29 and return on invested capital (ROIC) is -34.38%.
Return on Equity (ROE)-0.29
Return on Assets (ROA)-0.26
Return on Invested Capital (ROIC)-34.38%
Return on Capital Employed (ROCE)-0.34
Revenue Per Employee543.89K
Profits Per Employee-1.21M
Employee Count10
Asset Turnover0.12
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Alterity Therapeutics is ―. Alterity Therapeutics’s PEG ratio is 0.08.
PE Ratio―
PS Ratio11.76
PB Ratio1.51
Price to Fair Value1.51
Price to FCF-5.59
Price to Operating Cash Flow-3.11
PEG Ratio0.08
Income Statement
In the last 12 months, Alterity Therapeutics had revenue of 5.44M and earned -12.15M in profits. Earnings per share was 0.00.
Revenue5.44M
Gross Profit5.31M
Operating Income-14.57M
Pretax Income-12.08M
Net Income-12.15M
EBITDA-14.63M
Earnings Per Share (EPS)0.00
Cash Flow
In the last 12 months, operating cash flow was -10.71M and capital expenditures 0.00, giving a free cash flow of -10.71M billion.
Operating Cash Flow-10.71M
Free Cash Flow-10.71M
Free Cash Flow per Share>-0.01
Dividends & Yields
Alterity Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.93
52-Week Price Change10.00%
50-Day Moving Average0.01
200-Day Moving Average―
Relative Strength Index (RSI)46.99
Average Volume (3m)12.63M
Important Dates
Alterity Therapeutics upcoming earnings date is Feb 26, 2026, TBA (Confirmed).
Last Earnings DateFeb 28, 2025
Next Earnings DateFeb 26, 2026
Ex-Dividend Date―
Financial Position
Alterity Therapeutics as a current ratio of 12.98, with Debt / Equity ratio of 1.36%
Current Ratio12.98
Quick Ratio12.98
Debt to Market Cap<0.01
Net Debt to EBITDA2.26
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Alterity Therapeutics has paid 68.06K in taxes.
Income Tax68.06K
Effective Tax Rate>-0.01
Enterprise Valuation
Alterity Therapeutics EV to EBITDA ratio is -2.12, with an EV/FCF ratio of -2.70.
EV to Sales5.69
EV to EBITDA-2.12
EV to Free Cash Flow-2.70
EV to Operating Cash Flow-2.70
Balance Sheet
Alterity Therapeutics has $40.66M in cash and marketable securities with $155.46K in debt, giving a net cash position of $40.50M billion.
Cash & Marketable Securities$40.66M
Total Debt$155.46K
Net Cash$40.50M
Net Cash Per Share<$0.01
Tangible Book Value Per Share<$0.01
Margins
Gross margin is 96.32%, with operating margin of -267.96%, and net profit margin of -223.35%.
Gross Margin96.32%
Operating Margin-267.96%
Pretax Margin-222.10%
Net Profit Margin-223.35%
EBITDA Margin-269.05%
EBIT Margin-269.57%
Analyst Forecast
The average price target for Alterity Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target―
Price Target Upside―
Analyst ConsensusHold
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast63.46%